IndraLab

Statements

THBS1 binds CD47 and SIRPA. 13 / 13
| 13
sparser
"Given recent insights into the physiological functions of CD47, potential side effects of therapeutic CD47-antibodies such as B6H12, which inhibits both CD47-SIRP and CD47-TSP1 interactions, include altered blood pressure [ xref ], hemolytic anemia, and prothrombotic or antithrombotic activities [ xref , xref ]."
23101472
sparser
"Interestingly, both TSP-1 and SIRPα are interacting with CD47 during synaptogenesis xref , xref , xref , xref , which means that other mechanisms appear to be involved in CD47-dependent regulation of the type of nerve fiber growth investigated in the present study."
23049778
sparser
"However, CD47 modified nanoparticles showed a prominent anti-phagocytosis property in M1 cells that may in part be due to the complex signalling interactions of CD47 with SIRPα and TSP-1."
27197045
sparser
"The binding of CD47 to either SIRPα or TSP1 provides two anticancer strategies."
25734483
sparser
"On T cells, the CD47 interaction with either SIRPa or TSP-1 may also suppress T cells proliferation and activation [ xref , xref ]."
32882841
sparser
"Thus, we propose that treatment of tumor-bearing animals with CD47 blocking antibodies, which are known to inhibit both SIRPα and TSP1 binding to CD47, could directly modulate adaptive as well as innate anti-tumor immunity."
25297630
sparser
"TSP-1 and SIRP-α bind CD47 IgV loop xref and TSP-1 can inhibit SIRP-α-Fc binding to CD47 expressing-Jurkat cells xref ."
22870271
sparser
"Notably, the widely used CD47 blocking antibody B6H12 inhibits binding of both SIRPα and TSP1 to cell surface CD47 ( xref )."
25708195
sparser
"One approach to avoid these shortcomings is to identify and develop small molecule molecular probes and pretherapeutic agents that would (1) selectively target SIRPα or TSP1 interactions with CD47, (2) provide a route to optimize pharmacokinetics, reduce on-target toxicity and maximize tissue penetration, and (3) allow more flexible routes of administration."
31276567
sparser
"CD47 antibody B6H12 downregulates VEGFR2 and SHP-2 phosphorylation [ xref ] and CD47 binds SIRP α and TSP-1 to regulate the expression of VEGF and VEGFR2, thereby affecting the progression of atherosclerosis."
32733941
sparser
"However, preclinical studies using the CD47 antibody B6H12 indicate that some CD47 antibodies can block both TSP1 and SIRPα interactions with CD47 [ xref ]."
33925464
sparser
"This data is consistent with competitive binding of TSP1 and SIRPα to a single site on CD47, steric inhibition of binding to distinct but proximal sites, or allosteric inhibition ( xref )."
25708195
sparser
"Indeed, CD47 antibody targeting may affect NO pathway modulation and subsequent angiogenesis regulation, since a commonly used CD47-blocking antibody (clone B6H12) was previously shown to concomitantly disrupt both TSP-1:CD47 and CD47:SIRPα interactions ( xref )."
26578962